Sharenet Sites 
Sharenet Sites
Update on Divestment of Aspen’s European Thrombosis Business to Mylan
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)
UPDATE ON DIVESTMENT OF ASPEN’S EUROPEAN THROMBOSIS BUSINESS TO MYLAN
Shareholders are referred to the announcement of 8 September 2020 wherein it was confirmed that Aspen
Global Incorporated, incorporated in Mauritius, a wholly owned subsidiary of Aspen Holdings, had
concluded an agreement in terms whereof Mylan Ireland Limited would acquire the commercialisation
rights and related intellectual property in respect of Aspen’s Thrombosis Business in Europe(1) for a purchase
consideration of EUR 641.9 million, plus the cost of the related inventory (the “Transaction”).
Aspen is pleased to confirm that it has received confirmation that all conditions precedent requiring third
party consents and approvals for the Transaction have now been fulfilled, with the remaining conditions
precedent being within the control of the parties. The parties are mutually committed to closure of the
Transaction on 27 November 2020.
Footnote
(1) Excludes Russia and the other Commonwealth of Independent States countries
Durban
27 October 2020
Sponsor
Investec Bank Limited
Date: 27-10-2020 03:28:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
